Biologics have revolutionized cancer treatment, reversed the course of immune related conditions, and offered new hope for patients with compromised health conditions. Northway Biotech, an end-to-end biologics CDMO, supports its biopharmaceutical clients with a new, state-of-the-art, process development and cGMP manufacturing facility. Having scientific expertise that accelerates time to market and invested in technology supporting gene to drug product, Northway Biotech presents a virtual, grand opening experience on Wednesday, January 20, 2021, at 1:00 p.m. EST. Click here to register.
Business of Biotech kicks off the new year with an up-close-and-personal talk with biotech investor and CFO extraordinaire Allan Shaw. We talk through last year's ups and downs and do a little prognosticating on what we're feeling bullish about — from unprecedented regulatory action to exciting progress on the cell and gene front — as we head into the new year.
A conversation with John Wilkes (AstraZeneca), Clifford Berry (Takeda), Amy D. Wilson, Ph.D., (Biogen), and Jim Morris (NSF Health Sciences)
Human performance improvement requires special focus and deliberate action by management to move from an old construct of investigating error as a human failure to a new construct where error is a symptom of a problem to be understood, linked to the context in which the error took place, and it is the starting point of the investigation, not its conclusion.
White Paper |
By Monica M. Commerford, Ph.D.,Thermo Fisher Scientific
The curing potential of cell and gene therapies is driving the industry to gain a better understanding of the evolving regulatory guidelines for these products, in order to bring them to market faster.
White Paper |
By Agata Burzawa and Pamela Hamill, Ph.D.,MilliporeSigma
Because characterization and comparison of originator and biosimilar candidate monoclonal antibodies (mAbs) is challenging due to their complex and variable structures, a range of analytical techniques should be employed.
By Ben Madsen, Tony Hsiao, et al.,Thermo Fisher Scientific Bioproduction
Product yield, production cost, and development timeline demands require perfusion, intensified fed-batch processes, and adherent cell culture solutions that address the specific needs of diverse bioproduction processes.
It's important to understand that CROs do not typically manage the comprehensive clinical trial supply chain. This paper reviews seven clinical trial supply best practices to help ensure a successful trial.
Speed and flexibility are critical to succeed in the bioprocessing market. Plastics technology enables small-batch, single-use packaging solutions for customized drugs to serve a smaller patient population.